This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.
Our Use of Cookies
The site uses cookies to provide you with a more responsive and personalized service and to analyze site traffic. By using this site, you accept our use of cookies as described in our privacy policy. Please read our privacy policy for more information on the cookies we use, the processing of your personal data and how to delete or block the use of cookies.
Accept and Close
You are now leaving www.astellas.com/us. The website you are linking to is neither owned nor controlled by Astellas.
Astellas is not responsible for the content or services on this site.
Acquisition enables Astellas to fully utilize proprietary technology to produce pluripotent stem cells that have the potential to lower immunological rejection in numerous therapeutic areas
- A breadth of abstracts highlighting the acute myeloid leukemia treatment landscape, healthcare resource use and cost of care to be presented during oral and poster sessions -
- Grand Prize winner Hernâni Oliveira of Porto, Portugal will receive a $50,000 grant from Astellas plus a one-year nights and weekends membership to MATTER, a healthcare innovation community -
In the challenge's second year, five entrants will compete for a chance to win a Grand Prize of $50,000 from Astellas and a consultation with Robert Herjavec, star of ABC's Emmy Award-winning hit television show, Shark Tank
Solid Tumor Antibody-Drug Conjugate (ADC) Enfortumab Vedotin to be Evaluated as a Monotherapy in Patients Previously Treated with a Checkpoint Inhibitor
- Enzalutamide is the first androgen receptor-inhibitor to demonstrate a statistically significant improvement in metastasis-free survival (MFS) in this patient population in a randomized, controlled clinical trial
If approved, the combination therapy could potentially offer a new treatment option for patients whose overactive bladder symptoms are not adequately controlled on monotherapy
For the third consecutive year, the pharmaceutical company was named to the 2017 Great Place to Work® ranking among medium-sized multinational businesses across all industries in the country
.svg)
